PCSK9单克隆抗体逆转家族性高胆固醇血症患者单核细胞促炎表型
该研究评估PCSK9单克隆抗体降低LDL-C对家族性高胆固醇血症(FH)患者单核细胞表型和功能的影响。FH患者(n=22)单核细胞CCR2表达约为健康对照(n=18)的3倍,且与血浆LDL-C显著相关(r=0.709);经24周PCSK9单抗治疗(n=17)后,LDL-C降低49%,伴随细胞内脂质蓄积减少、CCR2表达下降及迁移能力逆转。结论提示FH患者单核细胞呈促炎表型,PCSK9单抗降LDL-C可抑制该表型。
要点
- FH患者单核细胞CCR2表达约为健康对照的3倍,且与血浆LDL-C显著相关(r=0.709)。
- 经24周PCSK9单抗治疗,血浆LDL-C降低49%,伴随单核细胞内脂质蓄积和CCR2表达减少。
- PCSK9单抗治疗逆转了FH患者单核细胞增强的迁移能力。
核心结论
- FH患者单核细胞呈促炎表型,PCSK9单抗降LDL-C治疗可抑制该表型。
- LDL-C降低伴随单核细胞内脂质蓄积减少,提示降LDL-C本身对循环单核细胞具有抗炎效应。
研究设计与样本
- 研究纳入FH患者(n=22,LDL 6.8 ± 1.9 mmol/L)和健康对照(n=18,LDL 2.9 ± 0.8 mmol/L),采用流式细胞术和跨内皮迁移实验评估单核细胞表型和功能。
- FH患者因他汀相关肌肉症状未使用他汀,接受PCSK9单克隆抗体治疗24周(n=17)。
主要发现
- FH患者单核细胞CCR2表达约为健康对照的3倍,CCR2表达与血浆LDL-C显著相关(r=0.709),并与细胞内脂质蓄积正相关。
- FH患者单核细胞体外迁移能力增强。
- 经24周PCSK9单抗治疗(n=17),血浆LDL-C降低49%,伴随细胞内脂质蓄积减少和CCR2表达下降。
- PCSK9单抗治疗逆转了FH患者单核细胞增强的迁移能力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Migration of monocytes into the arterial wall contributes to arterial inflammation and atherosclerosis progression. Since elevated low-density lipoprotein cholesterol (LDL-C) levels have been associated with activation of plasma monocytes, intensive LDL-C lowering may reverse these pro-inflammatory changes. Using proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) which selectively reduce LDL-C, we studied the impact of LDL-C lowering on monocyte phenotype and function in patients with familial hypercholesterolaemia (FH) not using statins due to statin-associated muscle symptoms. METHODS AND RESULTS: We assessed monocyte phenotype and function using flow cytometry and a trans-endothelial migration assay in FH patients (n = 22: LDL 6.8 ± 1.9 mmol/L) and healthy controls (n = 18, LDL 2.9 ± 0.8 mmol/L). Monocyte chemokine receptor (CCR) 2 expression was approximaterly three-fold higher in FH patients compared with controls. C-C chemokine receptor type 2 (CCR2) expression correlated significantly with plasma LDL-C levels (r = 0.709) and was positively associated with intracellular lipid accumulation. Monocytes from FH patients also displayed enhanced migratory capacity ex vivo. After 24 weeks of PCSK9 mAb treatment (n = 17), plasma LDL-C was reduced by 49%, which coincided with reduced intracellular lipid accumulation and reduced CCR2 expression. Functional relevance was substantiated by the reversal of enhanced migratory capacity of monocytes following PCSK9 mAb therapy. CONCLUSIONS: Monocytes of FH patients have a pro-inflammatory phenotype, which is dampened by LDL-C lowering by PCSK9 mAb therapy. LDL-C lowering was paralleled by reduced intracellular lipid accumulation, suggesting that LDL-C lowering itself is associated with anti-inflammatory effects on circulating monocytes.
引用
- Bernelot Moens SJ, Neele AE, Kroon J, et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. Eur Heart J. 2017. PMID: 28329114. doi:10.1093/eurheartj/ehx002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。